Prabir Roy-Chaudhury, MD, PhD, FASN
KidneyCure Board of Directors
Prabir Roy-Chaudhury MD, PhD, FRCP (Edin) is a Professor of Medicine and Co-Director of the University of North Carolina (UNC) Kidney Center. After graduating from the Armed Forces Medical College, Pune, India, he trained in Internal Medicine and Nephrology at the University of Aberdeen, Scotland and at the Beth Israel Hospital, Harvard Medical School, Boston, USA. In addition to being an active transplant nephrologist, Dr. Roy-Chaudhury’s main research interest is in uremic vascular biology (including both dialysis vascular access dysfunction and cardiovascular complications in kidney disease patients). He currently leads a translational research program in this area funded through the National Institutes of Health, the Veterans Administration research program, and through industry grants. Dr. Roy-Chaudhury has been the recipient of extensive NIH research grant funding, has received national and international awards, has published over 175 papers, and is a sought after invited speaker, both nationally and internationally.
Dr. Roy-Chaudhury has been actively involved in the public policy and administrative aspects of dialysis vascular access care and hemodialysis as a previous or current board member/councilor/committee chair for the American Society of Diagnostic and Interventional Nephrology, the Renal Network, the Interventional Nephrology Advisory Group of the American Society of Nephrology (ASN), the ASN Post Graduation Education Committee and the International Society of Nephrology-India and South Asia Committees, as well as being the previous President of the American Nephrologists of Indian Origin (ANIO).
Dr. Roy-Chaudhury was also the founding American Society of Nephrology co-chair of the Kidney Health Initiative, which is a public-private partnership between the ASN and the FDA, which aims to bring together nephrologists, industry partners, patient advocacy groups and regulatory agencies; in an attempt to facilitate the passage of drugs, devices and biologics into the kidney disease space.
Chief, Division of Nephrology, University of Arizona and Banner University Medical Centers-Tucson and South; Director, Arizona Kidney and Vascular Program; Nephrologist, Southern Arizona VA Health Care Center; American Society of Nephrology Co-Chair, Kidney Health Initiative; President American Nephrologists of Indian Origin; Founder and Chief Scientific Officer, Inovasc LLC
MBBS, Armed Forces Medical College, Pune, India, 1985
MSc (Clinical Pharmacology), University of Aberdeen, Scotland (UK), 1986
Nephrology Fellowship, Beth Israel Hospital, Harvard Medical School, 1996
PhD (Renal Medicine), University of Aberdeen, Scotland (UK), 1997
Internal Medicine Residency, University of Cincinnati, 1998
FRCP (Edin), Royal College of Physicians of Edinburgh, 2000
ASN Co-Chair, Kidney Health Initiative (KHI) 2012-2018; Member or Chair multiple KHI Committees, 2012-2018; Abstract Selection Committee Member or Chair for Vascular Access x 4 years and Bioengineering x 2 years; ASN Program Committee 2012; ASN PGE Committee, 2012-2018; ASN Board of Advisors and ASN Capitol Hill team 2013-2016; Interventional Nephrology Advisory Group, 2009-2015; X Prize Advisory Panel, 2014; ASN-Industry Innovation Panel, 2015; Co-Chair, Early Program on "Curing Kidney Disease", 2015; ASN Innovation and Discovery Task Force, 2017-2018; ASN-RPA Leadership Panel, 2018
NIH Study Sections: Chair for 10 Special Emphasis Panels for R-21 and SBIR/STTR grants
American Society of Diagnostic and Interventional Nephrology (ASDIN): Councilor 2007-2014; Chair Research Committee 2008-2018; Nominations Committee 2016-2018; International Committee 2013-2018
Vascular Access Society of the Americas: Member, Board of Directors 2008-2013 and 2018 onwards
Cardio Renal Society of the Americas: Member, Board of Directors, 2018 onwards
American Nephrologists of Indian Origin: Secretary, 2009-2015; President 2015 onwards
Editorial Boards: Clinical Nephrology (Section Editor Interventional Nephrology); Scientific Reports; Indian Journal of Nephrology; Journal of Vascular Access
University of Arizona (UA): Research and Innovation Committee; UA-Banner Research Negotiation team, Deans Research Council
Glaxo-Chem Prize, University of Aberdeen 1986; 7th John Cunio Memorial Lecture, University of Miami, 2006; Gerald Beathard State of the Art Address, ASDIN, 2011; Gerald Beathard Award, ASDIN, 2012; Health Care Heroes Finalist (Innovator; Cincinnati Business Courier), 2014; KS Chugh Oration, Indian Society of Nephrology 2015, Henry Lecture, Vascular Access Society of the Americas, 2018; Plenary Session talks at the Vascular Access Society (2015), Australia New Zealand Society of Nephrology (2015) and American Society of Artificial and Internal Organs (2018); Faculty election to Alpha Omega Alpha, University of Cincinnati, 2014; National Evidence Generation Committee (Chair Robert Califf, FDA Commissioner), 2016; International Professor, NTR University, Hyderabad, India; 1 US Patent pending, 3 Provisional Patents; 7 Invention Disclosures.
MRCP (UK) 1988; ABIM Internal Medicine Board Certified 1998; ABIM Nephrology Board Certified 1999
The main focus of the Arizona Kidney and Vascular Program (AKVP) which I direct, is on "Uremic Vascular Biology", both in the context of vascular access dysfunction and cardiovascular morbidity/mortality in CKD/ESRD patients. AKVP is a patient-centered, multi-disciplinary, translational initiative that includes basic science, translational science and clinical research/outcome domains. We aim to better understand the mechanisms involved in vascular access dysfunction and cardiovascular disease in CKD/ESRD, so that they can be modulated into novel drugs/devices (technology innovation) that target these clinical problems. We have been continuously funded through the NIH and VA for this research over the last decade.
It is a distinct personal honor and privilege to have been nominated for ASN Council. I am proud of the fact that I have trained and worked in three countries on three continents (India, the United Kingdom and the US), which has resulted in a more global and inclusive perspective (both for medicine and life). Although we face a large number of challenges in kidney disease, we also live in an era of unprecedented biological and technological innovation which we must apply to kidney disease, while at the same time keeping the patient perspective front and center.